Erectile Dysfunction affects more than 300 million men globally, with prevalence increasing due to ageing populations, lifestyle factors, and comorbidities such as diabetes and cardiovascular disease.

Global Market Overview:
‍
-Global ED market (prescription drugs): USD 5.3 billion (2025)
-Expected CAGR: 7.6% through 2030
-Dominated by oral PDE5 inhibitors (e.g. Tadalafil, Sildenafil)
-Growing interest in OTC and alternative formats (e.g. gummies, fast-dissolving strips)

Unmet Needs:

-Faster onset of action
-Reduced side effects
-Improved patient adherence
-Novel delivery formats with less stigma

Eve’s proprietary solubility platform targets reformulated Tadalafil in new delivery formats - starting with softgels and exploring OTC-compliant alternatives for specific markets.